PARP inhibitor resistance: The underlying mechanisms and clinical implicationsPARPiHomologous recombinationResistanceSynthetic lethalityDue to the DNA repair defect, BRCA1/2 deficient tumor cells are more sensitive to PARP inhibitors (PARPi) through the mechanism of synthetic lethality. At present, several...
[2] Dorling L,Carvalho S,Allen J,et al. Breast cancer risk genes-association analysis in more than 113,000 women [J]. N Engl J Med,2021,384(5):428-439. [3] Li H,Liu ZY,Wu N,et al. PARP inhibitor resistance:the under...
Pharmacological alteration also modulates PARPi inhibitor response. PARPi are substrates of multidrug resistance protein (MDR1, P-gp), encoded by ABCB1 gene [123]. Both in vivo and in vitro studies indicated the enhanced P-gp-mediated drug efflux contributed to the acquired resistance to PARPi ...
Bradley Monk, MD, FACOG, FACS:Another concept I want to talk about is that with all this maintenance therapy, particularly PARP inhibitors, there’s a concern that the mechanism of resistance to a PARP inhibitor may translate into the mechanisms of resistance of future cycles of chemotherapy. ...
resistance. Although the precise mechanisms underlying the increased expression of the P-gp efflux pump in relation to PARPi resistance are not fully understood, the restoration of PARPi sensitivity in tumours upon co-treatment with tariquidar, a P-gp inhibitor, supports the role of drug efflux ...
今天邀请到了河南省肿瘤医院-妇瘤科-陈红敏医生解读于2021年10月发表在BBA-REVIEWS ON CANCER的一篇题为《PARP inhibitor resistance in ovarian cancer: Underlying mechanisms and therapeutic approaches targeting the ATR/CHK1 pathway》的文章。 00:000:00音频 ...
resistance. Although the precise mechanisms underlying the increased expression of the P-gp efflux pump in relation to PARPi resistance are not fully understood, the restoration of PARPi sensitivity in tumours upon co-treatment with tariquidar, a P-gp inhibitor, supports the role of drug efflux ...
6. Li H, Liu ZY, Wu N, Chen YC, Cheng Q, Wang J. PARP inhibitor resistance: theunderlying mechanisms and clinical implications.Mol Cancer2020;19:107. 7. Gabrielson A, Tesfaye AA, Marshall JL, Pishvaian MJ, Sma...
et al. Mechanisms of therapy resistance in patient-derived xenograft models of brca1-deficient breast cancer. J. Natl Cancer Inst. 108, 1–12 (2016). Google Scholar Kondrashova, O. et al. Methylation of all BRCA1 copies predicts response to the PARP inhibitor rucaparib in ovarian ...
clinical trials are being conducted and have begun to yield results. For example, the POLO (Pancreatic Cancer Olaparib Ongoing) trial has demonstrated that the median progression-free survival was observably longer in the olaparib group than in the placebo group. However, PARP inhibitor resistance ...